These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20024640)

  • 61. Mild depression versus C-reactive protein as a predictor of cardiovascular death: a three year follow-up of patients with stable coronary artery disease.
    Rallidis LS; Varounis C; Sourides V; Charalampopoulos A; Kotakos C; Liakos G; Dagres N; Apostolou T; Anastasiou-Nana M
    Curr Med Res Opin; 2011 Jul; 27(7):1407-13. PubMed ID: 21568834
    [TBL] [Abstract][Full Text] [Related]  

  • 62. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany.
    Koenig W; Löwel H; Baumert J; Meisinger C
    Circulation; 2004 Mar; 109(11):1349-53. PubMed ID: 15023871
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality.
    Parrinello CM; Lutsey PL; Ballantyne CM; Folsom AR; Pankow JS; Selvin E
    Am Heart J; 2015 Aug; 170(2):380-9. PubMed ID: 26299237
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community.
    Melander O; Newton-Cheh C; Almgren P; Hedblad B; Berglund G; Engström G; Persson M; Smith JG; Magnusson M; Christensson A; Struck J; Morgenthaler NG; Bergmann A; Pencina MJ; Wang TJ
    JAMA; 2009 Jul; 302(1):49-57. PubMed ID: 19567439
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of Yugengtongyu Granules in Patients with Stable Coronary Artery Disease on Reducing Adverse Cardiovascular Events: A Double-Blind Controlled Trial.
    Wang D; Li C; Xu X; Xu H; Guo C; Wang J; Guo J; Huang L
    J Altern Complement Med; 2021 Feb; 27(2):142-149. PubMed ID: 33259734
    [No Abstract]   [Full Text] [Related]  

  • 66. Markers of inflammation and cardiovascular disease: clinical applications of C-reactive protein determination.
    Martínez VB; González-Juanatey JR
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():3-7. PubMed ID: 20000881
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.
    Chu AY; Guilianini F; Barratt BJ; Nyberg F; Chasman DI; Ridker PM
    Circ Cardiovasc Genet; 2012 Feb; 5(1):58-65. PubMed ID: 22230323
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A tale of three labels: translating the JUPITER trial data into regulatory claims.
    Ridker PM
    Clin Trials; 2011 Aug; 8(4):417-22. PubMed ID: 21835857
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.
    Mani P; Puri R; Schwartz GG; Nissen SE; Shao M; Kastelein JJP; Menon V; Lincoff AM; Nicholls SJ
    JAMA Cardiol; 2019 Apr; 4(4):314-320. PubMed ID: 30840024
    [TBL] [Abstract][Full Text] [Related]  

  • 70. hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients With Myocardial Infarction: a Healthcare-Based Study.
    Carrero JJ; Andersson Franko M; Obergfell A; Gabrielsen A; Jernberg T
    J Am Heart Assoc; 2019 Jun; 8(11):e012638. PubMed ID: 31140334
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
    Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
    Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
    [TBL] [Abstract][Full Text] [Related]  

  • 73. C-reactive protein levels in patients at cardiovascular risk: EURIKA study.
    Halcox JP; Roy C; Tubach F; Banegas JR; Dallongeville J; De Backer G; Guallar E; Sazova O; Medina J; Perk J; Steg PG; Rodríguez-Artalejo F; Borghi C
    BMC Cardiovasc Disord; 2014 Feb; 14():25. PubMed ID: 24564178
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis.
    Li Y; Zhong X; Cheng G; Zhao C; Zhang L; Hong Y; Wan Q; He R; Wang Z
    Atherosclerosis; 2017 Apr; 259():75-82. PubMed ID: 28327451
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA
    Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
    [TBL] [Abstract][Full Text] [Related]  

  • 76. C-reactive protein predicts future cardiovascular events in patients with carotid stenosis.
    Schlager O; Exner M; Mlekusch W; Sabeti S; Amighi J; Dick P; Wagner O; Koppensteiner R; Minar E; Schillinger M
    Stroke; 2007 Apr; 38(4):1263-8. PubMed ID: 17322087
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Utility of C-reactive protein for cardiovascular risk stratification across three age groups in subjects without existing cardiovascular diseases.
    Hamer M; Chida Y; Stamatakis E
    Am J Cardiol; 2009 Aug; 104(4):538-42. PubMed ID: 19660608
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
    Fellström BC; Jardine AG; Schmieder RE; Holdaas H; Bannister K; Beutler J; Chae DW; Chevaile A; Cobbe SM; Grönhagen-Riska C; De Lima JJ; Lins R; Mayer G; McMahon AW; Parving HH; Remuzzi G; Samuelsson O; Sonkodi S; Sci D; Süleymanlar G; Tsakiris D; Tesar V; Todorov V; Wiecek A; Wüthrich RP; Gottlow M; Johnsson E; Zannad F;
    N Engl J Med; 2009 Apr; 360(14):1395-407. PubMed ID: 19332456
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
    Everett BM; Glynn RJ; MacFadyen JG; Ridker PM
    Circulation; 2010 Jan; 121(1):143-50. PubMed ID: 20026779
    [TBL] [Abstract][Full Text] [Related]  

  • 80. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.